Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT07668557 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

BIOLOGICAL: Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide

Sponsor

iCell Gene Therapeutics